文献速递母胎医学产科

重新审视cfDNA与微阵列时代颈项透明层诊断检测的最佳截断值:维多利亚围产期记录链接研究结果

Reexamining the optimal nuchal translucency cutoff for diagnostic testing in the cell-free DNA and microarray era: results from the Victorian Perinatal Record Linkage study.
PubMed 文献 · Am J Obstet Gynecol · 2021-05-03

该研究基于澳大利亚维多利亚州81,244例单胎妊娠的回顾性记录链接,评估颈项透明层(NT)增大定义非典型染色体异常的最佳截断值。结果显示,按孕龄调整的NT阈值1.9 MoM或第99百分位在识别非典型染色体异常方面优于固定3.0 mm截断值。

要点

  • NT≥3.5 mm组非典型染色体异常频率为4.07%,显著高于3.0-3.4 mm组的0.37%和<3.0 mm组的0.09%。
  • NT≥3.0 MoM组非典型染色体异常频率为4.69%,高于1.9-2.9 MoM组的2.53%和<1.9 MoM组的0.09%。
  • 1.9 MoM与3.0 mm阈值均捕获22/93例(23.7%)非典型染色体异常,但1.9 MoM特异性更优。

核心结论

  • 按孕龄调整的NT阈值1.9 MoM或第99百分位在识别非典型染色体异常方面优于固定3.0 mm截断值。
  • NT增大胎儿若合并其他超声异常,非典型染色体异常风险增加三倍以上。

研究设计与样本

  • 回顾性研究,纳入2015年1月至2016年12月澳大利亚维多利亚州81,244例单胎妊娠,进行早孕期联合筛查。
  • 通过链接全州早孕期联合筛查、产前诊断操作及产后(流产儿和12月龄内婴儿)细胞遗传学结果,确定染色体异常频率。
  • 非典型染色体异常定义为除21、18、13、X、Y染色体整倍体异常外的任何主要染色体异常。

主要发现

  • NT≥3.5 mm组总主要染色体异常频率为29.94%(147/491),显著高于3.0-3.4 mm组(3.93%,21/534)和<3.0 mm组(0.09%,71/80,219)(P<.001)。
  • NT≥3.5 mm、3.0-3.4 mm和<3.0 mm组非典型染色体异常频率分别为4.07%(95%CI 2.51-6.22)、0.37%(95%CI 0.05-1.35)和0.09%(95%CI 0.07-0.11)。
  • NT≥3.0 MoM、1.9-2.9 MoM和<1.9 MoM组非典型染色体异常频率分别为4.69%(95%CI 2.17-8.71)、2.53%(95%CI 1.36-4.29)和0.09%(95%CI 0.07-0.11)。
  • NT>3.0 mm和>1.9 MoM对任何非典型染色体异常的阳性预测值分别为1/47和1/32。
  • 1.9 MoM阈值捕获0.87%胎儿,接近第99百分位。

关键数值与推荐

  • 非典型染色体异常频率在NT≥3.5 mm组为4.07%(95%CI 2.51-6.22),在3.0-3.4 mm组为0.37%(95%CI 0.05-1.35),在<3.0 mm组为0.09%(95%CI 0.07-0.11)。
  • 非典型染色体异常频率在NT≥3.0 MoM组为4.69%(95%CI 2.17-8.71),在1.9-2.9 MoM组为2.53%(95%CI 1.36-4.29),在<1.9 MoM组为0.09%(95%CI 0.07-0.11)。
  • NT>3.0 mm对非典型染色体异常的阳性预测值为1/47,NT>1.9 MoM为1/32。
  • 1.9 MoM与3.0 mm阈值均捕获22/93例(23.7%)非典型染色体异常,其中50.0%合并胎儿超声异常。

临床怎么用

  • 在cfDNA和微阵列时代,建议采用孕龄调整的NT阈值1.9 MoM或第99百分位替代固定3.0 mm,以优化非典型染色体异常的检出。
  • 对于NT增大且合并其他超声异常的胎儿,应告知非典型染色体异常风险增加三倍以上。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 仅纳入维多利亚州居民,结果外推需谨慎。
  • 诊断检测并非所有妊娠均进行,可能低估染色体异常频率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine recently recommended offering genetic counseling and diagnostic testing for enlarged nuchal translucency at ≥3.0 mm, regardless of previous negative screening with noninvasive prenatal testing. OBJECTIVE: This study aimed to perform a population-based, individual record linkage study to determine the optimal definition of an enlarged nuchal translucency for the detection of atypical chromosome abnormalities. STUDY DESIGN: This was a retrospective study of women resident in Victoria, Australia, undergoing combined first-trimester screening during the 24-month period from January 2015 to December 2016. Linkages between statewide results for combined first-trimester screening, prenatal diagnostic procedures, and postnatal cytogenetic results from products of conception and infants up to 12 months of age were used to ascertain the frequency and type of chromosome abnormality by gestation and nuchal translucency measurement. An atypical chromosome abnormality was defined as any major chromosome abnormality other than whole chromosome aneuploidy involving chromosomes 21, 18, 13, X, and Y. RESULTS: Of the 81,244 singleton pregnancies undergoing combined first-trimester screening, 491 (0.60%) had a nuchal translucency of ≥3.5 mm, 534 (0.66%) had a nuchal translucency of 3.0 to 3.4 mm, and 80,219 (98.74%) had a nuchal translucency of < 3.0 mm. When grouped by nuchal translucency multiples of the median (MoM), 192 (0.24%) had a nuchal translucency of ≥3.0 MoM, 513 (0.63%) had a nuchal translucency of 1.9 to 2.9 MoM, and 80,539 (99.13%) had a nuchal translucency of <1.9 MoM. A total of 1779 pregnancies underwent prenatal or postnatal diagnostic testing, of which 89.60% were performed by whole-genome single-nucleotide polymorphism chromosomal microarray. The frequency of total major chromosome abnormalities was significantly higher in the group with a nuchal translucency of ≥3.5 mm (147 of 491, 29.94%) than the group with a nuchal translucency of 3.0 to 3.4 mm (21 of 534, 3.93%) or a nuchal translucency of <3.0 mm (71 of 80,219, 0.09%) (P<.001). There were 93 atypical chromosome abnormalities in the total screened cohort. The frequency of an atypical chromosome abnormality was 4.07% (95% confidence interval, 2.51-6.22), 0.37% (95% confidence interval, 0.05-1.35), and 0.09% (95% confidence interval, 0.07-0.11) in the groups with a nuchal translucency of ≥3.5 mm, 3.0 to 3.4 mm, and <3.0 mm, respectively. The frequency of atypical chromosome abnormalities was 4.69% (95% confidence interval, 2.17-8.71), 2.53% (95% confidence interval, 1.36-4.29), and 0.09% (95% confidence interval, 0.07-0.11) in the groups with a nuchal translucency of ≥3.0 MoM, 1.9 to 2.9 MoM, and <1.9 MoM, respectively. When defining thresholds for offering diagnosis with chromosomal microarray at 11 to 13 weeks, both a nuchal translucency threshold of 1.9 MoM and a fixed threshold of 3.0 mm captured 22 of 93 fetuses (23.7%) with an atypical chromosome abnormality. Of these, 50.0% had a coexisting fetal abnormality on ultrasound. However, the gestation-specific threshold of 1.9 MoM had a better specificity than 3.0 mm. The positive predictive value of an enlarged nuchal translucency for any atypical chromosome abnormality was 1 in 47 for nuchal translucency of >3.0 mm and 1 in 32 for nuchal translucency of >1.9 MoM. Our nuchal translucency threshold of 1.9 MoM captured 0.87% of fetuses, thus approximating the 99th centile. CONCLUSION: A gestational age-adjusted nuchal translucency threshold of 1.9 MoM or 99th centile is superior to the fixed cutoff of 3.0 mm for the identification of atypical chromosome abnormalities. The risk of an atypical chromosome abnormality in a fetus with an enlarged nuchal translucency is more than tripled in the presence of an additional ultrasound abnormality.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hui L, Pynaker C, Bonacquisto L, et al. Reexamining the optimal nuchal translucency cutoff for diagnostic testing in the cell-free DNA and microarray era: results from the Victorian Perinatal Record Linkage study. Am J Obstet Gynecol. 2021. PMID: 33957116. doi:10.1016/j.ajog.2021.03.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。